Literature DB >> 26388532

Skin antisepsis with chlorhexidine-alcohol versus povidone iodine-alcohol, with and without skin scrubbing, for prevention of intravascular-catheter-related infection (CLEAN): an open-label, multicentre, randomised, controlled, two-by-two factorial trial.

Olivier Mimoz1, Jean-Christophe Lucet2, Thomas Kerforne3, Julien Pascal4, Bertrand Souweine5, Véronique Goudet6, Alain Mercat7, Lila Bouadma8, Sigismond Lasocki9, Serge Alfandari10, Arnaud Friggeri11, Florent Wallet11, Nicolas Allou12, Stéphane Ruckly13, Dorothée Balayn3, Alain Lepape11, Jean-François Timsit8.   

Abstract

BACKGROUND: Intravascular-catheter-related infections are frequent life-threatening events in health care, but incidence can be decreased by improvements in the quality of care. Optimisation of skin antisepsis is essential to prevent short-term catheter-related infections. We hypothesised that chlorhexidine-alcohol would be more effective than povidone iodine-alcohol as a skin antiseptic to prevent intravascular-catheter-related infections.
METHODS: In this open-label, randomised controlled trial with a two-by-two factorial design, we enrolled consecutive adults (age ≥18 years) admitted to one of 11 French intensive-care units and requiring at least one of central-venous, haemodialysis, or arterial catheters. Before catheter insertion, we randomly assigned (1:1:1:1) patients via a secure web-based random-number generator (permuted blocks of eight, stratified by centre) to have all intravascular catheters prepared with 2% chlorhexidine-70% isopropyl alcohol (chlorhexidine-alcohol) or 5% povidone iodine-69% ethanol (povidone iodine-alcohol), with or without scrubbing of the skin with detergent before antiseptic application. Physicians and nurses were not masked to group assignment but microbiologists and outcome assessors were. The primary outcome was the incidence of catheter-related infections with chlorhexidine-alcohol versus povidone iodine-alcohol in the intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT01629550 and is closed to new participants.
FINDINGS: Between Oct 26, 2012, and Feb 12, 2014, 2546 patients were eligible to participate in the study. We randomly assigned 1181 patients (2547 catheters) to chlorhexidine-alcohol (594 patients with scrubbing, 587 without) and 1168 (2612 catheters) to povidone iodine-alcohol (580 patients with scrubbing, 588 without). Chlorhexidine-alcohol was associated with lower incidence of catheter-related infections (0·28 vs 1·77 per 1000 catheter-days with povidone iodine-alcohol; hazard ratio 0·15, 95% CI 0·05-0·41; p=0·0002). Scrubbing was not associated with a significant difference in catheter colonisation (p=0·3877). No systemic adverse events were reported, but severe skin reactions occurred more frequently in those assigned to chlorhexidine-alcohol (27 [3%] patients vs seven [1%] with povidone iodine-alcohol; p=0·0017) and led to chlorhexidine discontinuation in two patients.
INTERPRETATION: For skin antisepsis, chlorhexidine-alcohol provides greater protection against short-term catheter-related infections than does povidone iodine-alcohol and should be included in all bundles for prevention of intravascular catheter-related infections. FUNDING: University Hospital of Poitiers, CareFusion.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26388532     DOI: 10.1016/S0140-6736(15)00244-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  53 in total

1.  Infection: Efficacy of chlorhexidine against catheter-related infections.

Authors:  Jessica K Edwards
Journal:  Nat Rev Nephrol       Date:  2015-10-06       Impact factor: 28.314

2.  A multimodality approach to prevent catheter-related bloodstream infections: the role of chlorhexidine-alcohol as a skin antiseptic before intravascular catheter insertion.

Authors:  Kwok M Ho
Journal:  Ann Transl Med       Date:  2015-12

3.  What's new in catheter-related infection: skin cleansing and skin antisepsis.

Authors:  Olivier Mimoz; Vineet Chopra; Jean-François Timsit
Journal:  Intensive Care Med       Date:  2016-02-03       Impact factor: 17.440

Review 4.  Antimicrobial Resistance to Agents Used for Staphylococcus aureus Decolonization: Is There a Reason for Concern?

Authors:  Gregory R Madden; Costi D Sifri
Journal:  Curr Infect Dis Rep       Date:  2018-06-07       Impact factor: 3.725

5.  What's new: prevention of acute dialysis catheter-related infection.

Authors:  Antoine Schneider; Ian Baldwin; Bertrand Souweine
Journal:  Intensive Care Med       Date:  2017-05-18       Impact factor: 17.440

6.  Complications of intravascular catheters in ICU: definitions, incidence and severity. A randomized controlled trial comparing usual transparent dressings versus new-generation dressings (the ADVANCED study).

Authors:  Silvia Calviño Günther; Carole Schwebel; Rebecca Hamidfar-Roy; Agnès Bonadona; Maxime Lugosi; Claire Ara-Somohano; Clémence Minet; Leïla Potton; Jean-Charles Cartier; Aurelien Vésin; Magalie Chautemps; Lenka Styfalova; Stephane Ruckly; Jean-François Timsit
Journal:  Intensive Care Med       Date:  2016-10-12       Impact factor: 17.440

7.  Antiseptic Agents Elicit Short-Term, Personalized, and Body Site-Specific Shifts in Resident Skin Bacterial Communities.

Authors:  Adam J SanMiguel; Jacquelyn S Meisel; Joseph Horwinski; Qi Zheng; Charles W Bradley; Elizabeth A Grice
Journal:  J Invest Dermatol       Date:  2018-05-09       Impact factor: 8.551

Review 8.  A state of the art review on optimal practices to prevent, recognize, and manage complications associated with intravascular devices in the critically ill.

Authors:  Jean-François Timsit; Mark Rupp; Emilio Bouza; Vineet Chopra; Tarja Kärpänen; Kevin Laupland; Thiago Lisboa; Leonard Mermel; Olivier Mimoz; Jean-Jacques Parienti; Garyphalia Poulakou; Bertrand Souweine; Walter Zingg
Journal:  Intensive Care Med       Date:  2018-05-12       Impact factor: 17.440

9.  New Insights into Predictors of Cardiac Implantable Electronic Device Infection.

Authors:  Hossein Sadeghi; Abolfath Alizadehdiz; Amirfarjam Fazelifar; Zahra Emkanjoo; Majid Haghjoo
Journal:  Tex Heart Inst J       Date:  2018-06-01

10.  Tolerability and Plasma Drug Level Monitoring of Prolonged Subcutaneous Teicoplanin Treatment for Bone and Joint Infections.

Authors:  Youssef El Samad; Jean-Philippe Lanoix; Youssef Bennis; Momar Diouf; Carlo Saroufim; Benoit Brunschweiler; Florence Rousseau; Cédric Joseph; Farida Hamdad; Mohamed Ait Amer Meziane; Simon Routier; Jean-Luc Schmit
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.